Product Name :
Nivolumab/Relatlimab
Search keywords :
Relatlimab
drugId :
null
Target Vo:
Lymphocyte activation gene 3 protein
Target Vo Short Name :
LAG3
Moa_Name:
Programmed cell death protein 1 blockers
First Approval Country :
United States
First Approval Date Filter:
2022
Origin Company_Name :
Bristol-Myers Squibb Company
Active Company_Name :
Bristol-Myers Squibb (China) Investment Co Ltd
Active Indication_Name:
Melanoma
In Active Indication_Name:
Colorectal Neoplasms
Termination Status :
China Termination Status :
Highest Status:
Approved
China Highest Status:
Phase 3 Clinical
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
BTK Antibody (YA816)
AIF Antibody (YA835)
SREBP1 Antibody: SREBP1 Antibody is a non-conjugated and Rabbit origined polyclonal antibody about 122 kDa, targeting to SREBP1. It can be used for WB,ELISA assays with tag free, in the background of Human, Mouse, Rat.